Quantitative Structure - Activity Relationships Study of Carbonic Anhydrase Inhibitors Using Logistic Regression Model

Document Type: Research Article

Authors

1 Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, I.R. IRAN

2 Department of Biophysics, Faculty of Science, Tarbiat Modares University, P.O. Box: 14115/175 Tehran, I.R. IRAN

3 Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, I.R. IRAN

Abstract

Binary Logistic Regression (BLR) has been developed as non-linear models to establish quantitative structure- activity relationships (QSAR) between structural descriptors and biochemical activity of carbonic anhydrase inhibitors. Using a training set consisted of 21 compounds with known ki values, the model was trained and tested to solve two-class problems as active or inactive on the basis of the predicted value for IC50. Many quantitative descriptors were generated to express the physicochemical properties of 21 compounds with optimized structures. After filtration of these descriptors, 39 of descriptors for carbonic anhydrase (CA, EC 4.2.1.1) isozyme IX (CAIX) and 45 for isozymeXII (CAXII) remained and were selected for QSAR study. Logistic regression was then used to non-linearly select the most important descriptors and to develop a model for prediction of IC50. To evaluate the performance of the established models, Jjackknife and self consistency tests were performed during implementation of the two model-building methods. The applied indices including accuracy, sensitivity, and specificity were 85%, 82% and 100% for CAIX and also 71%, 68% and 80% for CAXII respectively.The primary advantage of such an approach is the reduction of redundant variables and the consequent improvement in the efficiency of modeling.  

Keywords

Main Subjects


1] Fiore A.D., Simone G.D., Menchise V., Pedone C., Supuran C.T., Carbonic Anhydrase Inhibitors: X-ray Crystal Structure of a Benzenesulfonamide Strong CA II and CA IX Inhibitor Bearing a Pentafluorophenylaminothioureido Tail in Complex with Isozyme II, Bioorganic & Medicinal Chemistry Letters, 15, p.1937 (2005).

[2] Guzel O., Salman A., Supuran C.T., Synthesis of 2,4,6-Trimethylpyridinium Derivatives of 2- Hydrazinocarbonyl)-3-Aryl-1H-Indole-5-Sulfonamides Acting as Potent Inhibitors of the Tumor-Associated Isoform IX and XII, Bioorganic & Medicinal Chemistry Letters, 19, p.2931 (2009).

[3] Hemmateenejad B., Miri R., Jafarpour M., Tabarzad M., Exploring QSAR for the Inhibitory Activity of a Large Set of Aromatic /Heterocyclic Sulfonamides toward Four Different Isoenzymes of Carbonic Anhydrase, QSAR Comb. Sci., 10, p. 1065 (2007).

[4] Turkmen H., Durgun M., Yilmaztekin S., Emul M., Innocenti A., Vullo D.,  Scozzafava A. Supuran, C.T., Carbonic Anhydrase Inhibitors. Novel Sulfanilamide/Acetazolamide Derivatives Obtained by the Tail Approach and Their Interaction with the Cytosolic Isozymes I and II, and the Tumor-Associated Isozyme IX, Bioorganic & Medicinal Chemistry Letters, 15, P. 367 (2005).

[5] Carta F., Maresca A., Scozzafava A., Vullo D., Supuran C.T., Carbonic Anhydrase Inhibitors. Diazenylbenzenesulfonamides are Potent and Selective Inhibitors of the Tumor-Associated Isozymes IX and XII over the Cytosolic Isoforms I and II, Bioorganic & Medicinal Chemistry, 17, p. 7093 (2009).

[6] Fukumura D., Chen Y., Gohongi T., Seed B., Jain R.K., Hypoxia and Acidosis Independently Up-Regulate Vascular Endothelial Growth Factor Transcription in Brain Tumors in Vivo, Cancer Res., 61, p. 6020 (2001).

[7] Giatromanolaki A., Koukourakis M.I., Sivridis E., Pastorek J., Wykoff C.C., Gatter K. C., Harris A.L., Expression of Hypoxia-Inducible Carbonic Anhydrase-9 Relates to Angiogenic Pathways and Independently to Poor Outcome in Non-Small Cell Lung Cancer, Cancer Res., 61, p. 7992 (2001).

[8] Chia S.K., Wykoff C.C., Watson P. H., Han C., Leek  R.D., Pastorek J., Gatter K.C., Ratcliffe P., Harris A.L., Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase ix, in Invasive Breast Carcinoma, J. Clin. Oncol., 19, p. 3660 (2001).

[9] Vullo D., Franchi M., Gallori E. Supurana, C.T., Carbonic Anhydrase Inhibitors: Inhibition of the Tumor-Associated Isozyme IX with Aromatic and Heterocyclic Sulfonamides, Bioorganic & Medicinal Chemistry Letters, 13, p. 1005 (2003).

[10] Winum J., Cecchi A., Montero J., Inoccenti A., Carbonic Anhydrase Inhibitors. Synthesis and Inhibition of Cytosolic/Tumor-Associated Carbonic Anhydrase Isozymes I, II, and IX with Boron-Containing Sulfonamides, Sulfamides, and Sulfamates: Toward Agents for Boron Neutron Capture Therapy of Hypoxic Tumors, Bioorg. Med. Chem, 15, p. 3302 (2005).

[11] Mincione F., Starnotti M., Masini E., Bacciottini L., Scrivanti C., Casini A., Vullo D., Scozzafava A., Supuran C.T., Carbonic Anhydrase Inhibitors: Design of Thioureido Sulfonamides with Potent Isozyme II and XII Inhibitory Properties and Intraocular Pressure Lowering Activity in a Rabbit Model of Glaucoma, Bioorg. Med. Chem. Lett., 15, p. 3821 (2005).

[12]Garaj V., Puccetti L., Fasolis G., Winum J.Y., Montero J.L., Carbonic Anhydrase Inhibitors:
Novel Sulfonamides Incorporating 1,3,5-Triazine Moieties as Inhibitors of the Cytosolic and
Tumour-Associated Carbonic Anhydrase Isozymes I, II and IX, Bioorg. Med. Chem., 15, p. 3102 (2005).

[13] Thakur A., Thakur M., Khadikar P.V., Supuran C.T., Sudele P., QSAR Study on Benzenesulphonamide Carbonic Anhydrase Inhibitors: Topological Approach Using Balaban Index, Bioorg. Med. Chem., 12, p. 789 (2004).

[14] Rusconi S., Innocenti A., Vullo D., Mastrolorenzo A., Scozzafava A., Supuran C.T., Carbonic Anhydrase Inhibitors. Interaction of Isozymes I, II, IV, V, and IX with Phosphates, Carbamoyl Phosphate, and the Phosphonate Antiviral Drug Foscarnet, Bioorg. Med. Chem. Lett., 14, p. 5763 (2004).

[15] Scozzafava A., Menabuoni L., Mincione F., Supuran C.T., Carbonic Anhydrase Activators: High Affinity Isozymes I, II, and IV Activators, Incorporating a β-Alanyl-histidine Scaffold, J. Med. Chem., 45, p. 1466 (2002).

[16] Abdel-Hamid M.K., Abdel- Hafez A.A., El-Koussi N.A., Mahfouz N.M., Innocenti A., Supuran C.T., Design, Synthesis, and Docking Studies of New 1, 3, 4-Thiadiazole-2- Thione Derivatives with Carbonic Anhydrase Inhibitory Activity, Bioorganic & Medicinal Chemistry, 15, p. 6975 (2007).

[17] Czewski S., Innocenti A., Ski J.S., Kornick A., Brzozowski Z., Supuran C.T., Carbonic Anhydrase Inhibitors: Inhibition of Human Cytosolic Isozymes I and II and Tumor-Associated Isozymes IX and XII with S-Substituted 4-Chloro-2-Mercapto- 5-Methyl-Benzenesulfona- Mides, Bioorganic & Medicinal Chemistry, 16, p. 3933 (2008).

[18] Bruno-Blanch L., Galvez J., Garcia-Domenech R., Topological Virtual Screening: A Way to Find New Anticonvulsant Drugs from Chemical Diversity,  Bioorg. Med. Chem. Lett., 13, p. 2749 (2003).

[19] Jaiswal M., Khadikar P.V., Supuran C.T., Topological Modeling of Lipophilicity, Diuretic Activity, and Carbonic Inhibition Activity of Benzene Sulfonamides: a Molecular Connectivity Approach, Bioorganic & Medicinal Chemistry Letters., 14, p. 5661 (2004).

[20] Debnath A.K., Ghose A.K, Viswanadhan V.N., Eds., In "Combinatorial Library Design and Evaluation: Principles Software Tools and Applications in Drug Discovery", Marcel Dekker: New York, p. 73 (2001).

[21] Mohebi A., Sobbif A., Autamated Analysis of Pressure Build up Tests by Phase Redistribution, Iraninan Journal of Chemistry  and Chemical Engineering (IJCCE), 15(1), p. 38 (1996). 

[22] Kumar S., Singh V., Tiwari M., Quantitative Structure Activity Relationship Studies of Sulfamide Derivatives as Carbonic Anhydrase Inhibitor: As Antiglaucoma Agents, Medicinal Chemistry, 3, p. 379 ( 2007).

[23] Hosmer D.W., Lemeshow S., “Applied Logistic Regression”, Wiley, New York (1989).

[24] Abdolmaleki P., Mokhtari Dizagi M., Vahead  M.R., Gity M., Logistic Discriminant Anlysis of Breast Cancer Using Ultrasound Measurements, Iran. J. Radiat. Res., 2, p. 1 (2004).

[25] Caballero J., Garriga M., Fernandez M., 2D Autocorrelation Modeling of the Negative Inotropic Activity of Calcium Entry Blockers Using Bayesian- Regularized Genetic Neural Networks, Bioorgan. Med. Chem., 14, p. 3330 (2006).

[26] Todeschini R., Consonni V. “Handbook of Molecular Descriptors”, Wiley-VCH (2000).

[27] Hemmer M.C., Steinhauer V., Gasteiger J., Deriving the 3D Structure of Organic Molecules from Their Infrared Spectra, Vib. Spectrosc., 19, p. 151 (1999).

[28] Todeschini R., Consonni V., “Molecular Descriptors for Chemoinformatics”, WILEY-VCH; John wiley (2009).

[29] Puta R., Xua Q.S., Massarta D.L., Vander Heydena Y., Multivariate Adaptive Regression Splines (MARS) in Chromatographic Quantitative Structure-Retention Relationship Studies, Journal of Chromatography A., 1055, p. 11 (2004).

[30] Melagraki G., Afantitis A., Sarimveis H., Igglessi-Markopouloua O. Supuran C.T., QSAR Study on Para-Substituted Aromatic Sulfonamides as Carbonic Anhydrase II Inhibitors Using Topological Information Indices, Bioorganic & Medicinal Chemistry, 14, p. 1108 (2006).

[31] Rohan G., Jyoti P., Neetu S., Yogesh P. A., Arun K.G.,Insights Through Molecular Modeling Into the Structural Requirement of Phenyl(6-Phenylpyrazin-2-yl)Methanone Derivatives as Aldose Reductase Inhibitors,  International Journal of Drug Design and Discovery., 2, p. 575 (2011).

[32] Liane S., Maykel P., Marta T., 2D-Autocorrelation Descriptors for Predicting Cytotoxicity of Naphthoquinone Ester Derivatives Against Oral Human Epidermoid Carcinoma,  Bioorganic & Medicinal Chemistry, 15, p. 3565 (2007).

[33] Deeb O., Goodarzi M., Quantum Chemical QSAR Models to Distinguish Between Inhibitory Activities of Sulfonamides Against Human Carbonic Anhydrases I and II and Bovine IV Isozymes, Chem Biol Drug Des., 79, p. 514 (2011).

[34] Jantschi L., Daniela Bolboaca S., Modelling the Inhibitory Activity on Carbonic Anhydrase IV of Substituted Thiadiazole- and Thiadiazoline-Disulfonamides: Integration of Structure Information, Rev Electron Biomed / Electron J Biomed, 2, p. 22 (2006).

[35] Clare B.W., Supuran C.T., A Perspective on Quantitative Structure-Activity Relationships and Carbonic Anhydrase Inhibitors, Expert Opin Drug Metab Toxicol.,2, p. 113 (2006).

[36] Mattioni B.E., Jurs P.C., Development of Quantitative Structure-Activity Relationship and Classification Models for a Set of Carbonic Anhydrase Inhibitors, J. Chem. Inf. Comput. Sci., 42, P. 94 (2002).

[37]  Bakken G.A., Jurs P.C., QSARs for 6-Azasteroids as Inhibitors of Human Type 1 5r-Reductase: Prediction of Binding Affinity and Selectivity Relative to 3-BHSD, J. Chem. Inf. Comput. Sci., 41, p. 255 (2001).


Volume 32, Issue 2
May and June 2013
Pages 19-29